AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Shares in biotechnology company Apogee Therapeutics ($APGE) are set to start the new week off in great shape on reports that it could be swallowed ...

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is running a late-stage cancer study called “An Open-Label, Randomized, ...

AbbVie’s New Phase 3 Colorectal Cancer Trial Puts ABBV-400 in the Late-Stage Spotlight

High prices and a strong job market mean rate cuts will not happen soon, which could cause wide swings in the stock market. Since these trends add ...

5 Powerhouse Dividend Stocks with Huge Cash Payouts to Help Investors Crush Surging Inflation

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is launching a new early-stage trial focused on children with har...

AbbVie Targets Pediatric AML With New Pivekimab Sunirine Trial, Signaling Deeper Oncology Push

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s new study, officially titled “Phase 2/3 Open Label Randomized Study of...

AbbVie Targets Tough Pancreatic Cancer With New Phase 2/3 Telisotuzumab Study

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on C4 Therapeutics (CCCC), AbbVie (ABBV) and Hinge Heal...

Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV)

JPMorgan’s ($JPM) two popular income ETFs, the JPMorgan Equity Premium Income ETF ($JEPI) and the JPMorgan Nasdaq Equity Premium Income ETF ($JEPQ)...

JEPI vs. JEPQ: Two Active Income ETFs with Over 20% Growth Potential

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) an...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a Phase 1 study titled “Assessment of the Relative ...

AbbVie Advances ABBV-932 With Completed Bioavailability Study, Supporting Long-Term Pipeline Value

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a real world study in China tracking how its oral d...

AbbVie Completes Real World Upadacitinib Study in China: What Investors Should Watch

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has updated a Phase 1b study called “A Phase 1b Efficacy and Safety Stud...

AbbVie Ends Early Lung Cancer Trial for ABBV-647, Trimming One Oncology Upside Lever

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX) and AbbVie (ABBV) with bullis...

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)

Analysts fell to the sidelines weighing in on Astellas Pharma (ALPMF), AbbVie (ABBV) and Replimune Group (REPL) with neutral ratings, indicating th...

Analysts Offer Insights on Healthcare Companies: Astellas Pharma (OtherALPMF), AbbVie (ABBV) and Replimune Group (REPL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus A...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)

Abbvie ($ABBV) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, First-in-Human, Single Ascending Dose, Open-label...

AbbVie Advances New Autoimmune Drug ABBV-519 Into First-in-Human Trial, Signaling Next Wave in Immunology

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has launched a first in human Phase 1 study titled “A First in Hu...

AbbVie Expands Early Pipeline With New First-in-Human Study for ABBV-1451

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is launching an ambitious late-stage eye study called NAAVIGATE, formall...

Market Cap	$405.55B	P/E Ratio	15.14
52W High	$244.81	52W Low	$181.73
Div Yield	692.0%	Payout Ratio	328.9%
EPS Growth 3Y	-29.1%	52W Position	55.1%
Overall Score	61	Value Score	60
Quality Score	44	Technical Score	81

EPS Current Est	$14.3	EPS Next Est	$16.3
EPS Growth Est	+14.0%	DPS Growth 3Y	5.2%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$216.49	-2.14%	9.65M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$216.49	-2.1%	9.65M
3
4
5
6

ABBV

ABBV

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel